Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their …
N Schlesinger, RE Alten, T Bardin… - Annals of the rheumatic …, 2012 - Elsevier
Objectives Gouty arthritis patients for whom non-steroidal anti-inflammatory drugs and
colchicine are inappropriate have limited treatment options. Canakinumab, an anti-
interleukin-1β monoclonal antibody, may be an option for such patients. The authors
assessed the efficacy/safety of one dose of canakinumab 150 mg (n= 230) or triamcinolone
acetonide (TA) 40 mg (n= 226) at baseline and upon a new flare in frequently flaring patients
contraindicated for, intolerant of, or unresponsive to non-steroidal anti-inflammatory drugs …
colchicine are inappropriate have limited treatment options. Canakinumab, an anti-
interleukin-1β monoclonal antibody, may be an option for such patients. The authors
assessed the efficacy/safety of one dose of canakinumab 150 mg (n= 230) or triamcinolone
acetonide (TA) 40 mg (n= 226) at baseline and upon a new flare in frequently flaring patients
contraindicated for, intolerant of, or unresponsive to non-steroidal anti-inflammatory drugs …